论文部分内容阅读
应用流式细胞仪和抗血小板膜糖蛋白（GP）Ⅰb及GPⅡb／Ⅲa．单克隆抗体，测定了尿毒症患者和正常人血小板表面GPⅠb的量以及静息和用ADP活化条件下，血小板膜GPⅡb／Ⅲa的量。结果表明，尿毒症组血小板膜GPⅠb的量与对照组相比，无显著性差异（P＞0．05）；在静息和活化状态下，尿毒症组血小板膜GPⅡb／Ⅲa的量与正常对照组相比，也无显著性差异（P＞0．05），并且尿毒症组血小板以ADP活化后，其GPⅡb／Ⅲa表达的量与血浆肌酐或尿素氮水平无显著相关性（r＝－0．154，P＞0．05；r＝－0．177，P＞0．05）。提示尿毒症患者血小板膜GPⅠb和GPⅡb／Ⅲa的量无明显异常。
Flow cytometry and anti-platelet glycoprotein (GP) Ib and GPIIb / IIIa were used. Monoclonal antibodies were used to determine the amount of GPIb on the surface of platelets in patients with uremia and in normal subjects and the amount of platelet membrane GPIIb / IIIa resting and activated with ADP. The results showed that the amount of platelet membrane GPIb in uremia group had no significant difference compared with the control group (P> 0.05). Under resting and activated conditions, the amount of platelet membrane GPIIb / IIIa in uremia group was significantly higher than that in control group (P> 0.05). There was no significant correlation between GPⅡb / Ⅲa expression and plasma creatinine or urea nitrogen level after platelet ADR activation in uremia patients (r = -0 .154, P> 0.05; r = -0.177, P> 0.05). Prompt uremic patients with platelet membrane GP Ⅰ b and GP Ⅱ b / Ⅲ a the amount of no significant abnormalities.